Corneal allotransplantation, a key procedure in ophthalmology, involves transplanting corneal tissue from a deceased donor to a recipient with corneal damage or disease. This surgical intervention aims to restore vision by replacing damaged or diseased corneal tissue with healthy donor tissue. The procedure has evolved significantly with advancements in surgical techniques and immunosuppressive therapies, which help reduce the risk of rejection. Success rates are generally high due to the cornea's unique immune privilege, minimizing the need for long-term immunosuppression compared to other organ transplants. Post-operative care focuses on monitoring for signs of rejection and ensuring optimal healing. Despite its efficacy, challenges such as donor shortages and the need for skilled ophthalmic surgeons remain. Continued research aims to enhance outcomes and accessibility, making corneal allotransplantation a crucial treatment option for restoring vision in patients with corneal disease.







Title : Why a paediatric orthoptic oncology service matters
Shenika Tailor, University Hospitals of Leicester NHS Trust, United Kingdom
Title : Stereotactic radiotherapy for wet age-related macular degeneration: year 4 results of a randomised, double-masked, sham-controlled trial
Tim Jackson, King’s College London, United Kingdom